Eagan, Minnesota--(Newsfile Corp. - April 27, 2023) - Dynatronics Corporation (NASDAQ: DYNT), a leading manufacturer of athletic training, physical therapy, and rehabilitation products, today announced that the company will release financial results for its third quarter of fiscal year 2023 on Thursday, May 11, 2023 before the market opens.
The company will subsequently hold a conference call and webcast, consisting of prepared remarks by management, a slide presentation, and a question-and-answer session with analysts, at 8:00 AM ET on Thursday, May 11, 2023, to review its third quarter results.
Interested persons may access the live conference call by dialing 1-800-319-4610 (U.S./Canada callers) or 1-604-638-5340 (international callers). To join the call, it is recommended that participants call or log in 10 minutes ahead of the scheduled start time to ensure proper connection, and simply ask to join the Dynatronics call. No passcode is required.
The live webcast and slide presentation can be accessed via the company's Investor Relations website under the Events & Presentations tab at https://investors.dynatronics.com/services.The webcast will be archived on the website for future viewing.
About Dynatronics Corporation
Dynatronics is a leading medical device company committed to providing high-quality restorative products designed to accelerate achieving optimal health. The Company designs, manufactures, and sells a broad range of products for clinical use in physical therapy, rehabilitation, pain management, and athletic training. Through its distribution channels, Dynatronics markets and sells to orthopedists, physical therapists, chiropractors, athletic trainers, sports medicine practitioners, clinics, hospitals, and consumers. The Company's products are marketed under a portfolio of high-quality, well-known industry brands including Bird & Cronin®, Solaris™, Hausmann®, Physician's Choice®, and PROTEAM™, among others. More information is available at www.dynatronics.com.
CONTACT:
Dynatronics Corporation
This email address is being protected from spambots. You need JavaScript enabled to view it.
For additional information, please visit: www.dynatronics.com.
Connect with Dynatronics on LinkedIn.
| Last Trade: | US$0.10 |
| Daily Change: | -0.006 -5.66 |
| Daily Volume: | 9,496 |
| Market Cap: | US$726K |
February 08, 2024 January 15, 2024 November 09, 2023 October 30, 2023 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
